PF-303

• Description:

  PF-303 is a potent, oral inhibitor of Bruton's tyrosine kinase (BTK) (IC50=0.64 nM) . The melamine portion of PF-303 forms a covalent bond with BTK's Cys481, which is reversible and exhibits a high selectivity compared to irreversible covalent BTK inhibitors. PF-303 can be used to model and study the effects of BTK inhibition on the mature immune system, including effects on B-cell subsets, antibody responses, and T-cell-mediated activation[1][2].

• UNSPSC:

  12352005

• Target:

  Btk

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/pf-303.html

• Smiles:

  NC(C1=C(N)N([C@H]2CN(CCC2)C#N)N=C1C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl)=O

• Molecular Formula:

  C22H21ClN6O2

• Molecular Weight:

  436.89

• References & Citations:

  [1]Benson M J, et al. Modeling the clinical phenotype of BTK inhibition in the mature murine immune system[J]. The Journal of Immunology, 2014, 193 (1) : 185-197.|[2]Schnute M E, et al. Aminopyrazole carboxamide bruton’s tyrosine kinase inhibitors. irreversible to reversible covalent reactive group tuning[J]. ACS Medicinal Chemistry Letters, 2018, 10 (1) : 80-85.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1609465-78-2]